StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb (BMY) Raises Accelerated Buyback to $7B, to De-Lever Balance Sheet
August 26, 2019 6:37 AM
With Amgen's deal to acquire Celgen's OTEZLA, Bristol-Myers Squibb (NYSE: BMY) announced that it is increasing its previously planned $5 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Hot Buybacks
Stock Buybacks
Next Articles
UPDATE: Bristol-Myers Squibb (BMY), Presage Biosciences Announce Research Collaboration for Phase O Studies of Novel Cancer Agents Utilizing CIVO Technology
August 27, 2019 8:03 AM
Bristol-Myers Squibb (BMY) Gains 5% on Celgene's Deal to Sell Otezla to Amgen
August 26, 2019 6:50 AM